Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L). Tachihara M, Shoda H, Akazawa Y, Ota T, et al. Lung Cancer 2025;206:108637.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tachihara M, Shoda H, Akazawa Y, Ota T, et al. Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L). Lung Cancer 2025;206:108637.
PMID: 40602202